Monthly Archives: May 2014

Genprex Begins Phase II Clinical Trial for Lung Cancer

AUSTIN, TX, May 20, 2014 – Genprex, Inc. announced today that it has enrolled the first patient in a clinical trial evaluating its lead product candidate Oncoprex® in combination with erlotinib (Tarceva®) for late-stage lung cancer patients. Oncoprex is a targeted biologic incorporating the pan-kinase inhibitor TUSC2, which inhibits oncogenic kinases via multiple pathways.

Read More